Morepen Laboratories Limited is all set to start the commercial production of Sputnik V Coronavirus vaccine within 4-6 weeks subject to product approvals and regulatory permissions.

Earlier this month, The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund and Morepen Laboratories Limited announced the production of the test batch of the Russian Sputnik V coronavirus vaccine in an exclusive facility in the state of Himachal Pradesh. The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval.

The company has tied with The Russian Direct Investment Fund (RDIF) for the expansion of production of Sputnik V vaccine in Himachal Pradesh.

Sushil Suri, Managing Director and Chairman said, “Our partnership with RDIF to manufacture Sputnik vaccine in India is a big milestone for the company. We have a capacity to manufacture up to 250 million dose per annum that can be ramped up to 500 million doses per annum. We remain committed to fight the battle of COVID and gear ourselves for fast vaccination of the nation. Morepen’s commitment towards this project is a step forward towards entry into biosimilars and other biologicals.”

Morepen is a leading manufacturer of high-quality APIs, Home Diagnostics, Formulations, and OTC products in north India. All the manufacturing facilities of the company are in the state of Himachal Pradesh and meet the latest international standards.

The company’s both API facilities at Masulkhana and Baddi are approved by USFDA and other regulatory bodies of Europe, Asia, and Australia. The company’s manufacturing facility at Baddi comprises a scientifically integrated complex of 10 plants, each with a specific product profile.